• for investors
  • for entrepreneurs
  • companies
  • news
  • about us
Ochre Bio signs $1B deal with Boehringer Ingelheim to develop liver disease drugs

Ochre Bio signs $1B deal with Boehringer Ingelheim to develop liver disease drugs

by Francisca Peixoto | Apr 22, 2024 | Uncategorized

Our portfolio company Ochre Bio just signed a $1B partnership with Boehringer Ingelheim. Boehringer is a top 20 biopharmaceutical company by revenue and is the world’s largest private biopharma company, it is also a leader in liver disease R&D and has substantial...
InCephalo appoints Dr. Lorenz Mayr as new Chair

InCephalo appoints Dr. Lorenz Mayr as new Chair

by Francisca Peixoto | Apr 5, 2024 | Uncategorized

Our portfolio company InCephalo just appointed Dr. Lorenz Mayr as their new Chair. As the new Chairman of InCephalo, Dr. Lorenz Mayr brings his incredible experience in big names such as Bayer, Novartis, AstraZeneca, and Syncona. We, here at LifeLink Ventures, can’t...
Ochre Bio signs $1B deal with Boehringer Ingelheim to develop liver disease drugs

Ochre Bio’s interview with Judy Khan Shaw from the NYSE

by Francisca Peixoto | Apr 5, 2024 | Uncategorized

The CEO of our portfolio company Ochre Bio just did an interview with Judy Khan Shaw from the New York Stock Exchange. As published by NYSE on LinkedIn here: “Ochre Bio is on a mission to revolutionize liver disease treatment. Co-Founder + CEO Jack O’Meara...
LifeLink Ventures participates in BIO-EUROPE SPRING

LifeLink Ventures participates in BIO-EUROPE SPRING

by Francisca Peixoto | Mar 19, 2024 | Uncategorized

Our CEO and Co-founder, Francisca Peixoto, was a moderator, on March 19th, 2024, in a panel at this year’s BIO-EUROPE SPRING. The panel theme was named “In sync or offbeat: are the expectations of VCs and entrepreneurs aligned?”. This panel had the...
2023 Annual Biotech Report – LifeLink Ventures

2023 Annual Biotech Report – LifeLink Ventures

by Francisca Peixoto | Jan 5, 2024 | Uncategorized

As we start the new year, LifeLink Ventures releases its 2023 Annual Biotech Report. We wish to connect private investors with emerging technologies that address global health challenges. To do so, first we must bring our investors closer to the biotech world. Learn...
« Older Entries
Next Entries »

contact us

Barcelona Spain

  • Follow
  • Follow

navigate

  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us

legal conditions

  • Legal notice
  • Cookies policy
  • Privacy policy
  • Credits
  • home
  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us